Literature DB >> 29981283

Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study.

Shruti Chaturvedi1, Djamila Labib Ghafuri2, Natalie Jordan2,3, Adetola Kassim2,3, Mark Rodeghier4, Michael R DeBaun2,5.   

Abstract

Chronic end-organ complications result in morbidity and mortality in adults with sickle cell disease (SCD). In a retrospective-prospective cohort of 150 adults with SCD who received standard care screening for pulmonary function abnormalities, cardiac disease, and renal assessment from January 2003 to 2016, we tested the hypothesis that clustering of end-organ disease is common and multiple organ impairment predicts mortality. Any end-organ disease occurred in 59.3% of individuals, and 24.0% developed multiple organ (>1) end-organ disease. The number of end-organs affected was associated with mortality (P ≤ .001); 8.2% (5 of 61) of individuals with no affected end-organ, 9.4% (5 of 53) of those with 1 affected organ, 20.7% (6 of 29) of those with 2 affected end-organs, and 85.7% (6 of 7) with 3 affected end-organs died over a median follow up period of 8.7 (interquartile range 3.5-11.4) years. Of the 22 individuals who died, 77.3% had evidence of any SCD-related end-organ impairment, and this was the primary or secondary cause of death in 45.0%. SCD-related chronic impairment in multiple organs, and its association with mortality, highlights the need to understand the common mechanisms underlying chronic end-organ damage in SCD, and the urgent need to develop interventions to prevent irreversible end-organ complications in SCD.
© 2018 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2018        PMID: 29981283     DOI: 10.1002/ajh.25202

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

1.  Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis.

Authors:  Michael R DeBaun; Djamila L Ghafuri; Mark Rodeghier; Poulami Maitra; Shruti Chaturvedi; Adetola Kassim; Kenneth I Ataga
Journal:  Blood       Date:  2018-12-10       Impact factor: 22.113

2.  Incorporating low-cost spirometry testing of pulmonary function into comprehensive care for children with sickle cell anemia in northwestern Nigeria: a multicountry collaboration for achieving a sustainable initiative.

Authors:  R Aliyu Zubair; L G Dogara; M Arigliani; C Zuiani; A Dache Sunday; R C Audu; Z Sani; H Dadan-Garba; B P D Inusa
Journal:  Blood Adv       Date:  2018-11-30

3.  Validation of a composite vascular high-risk profile for adult patients with sickle cell disease.

Authors:  Mehdi Nouraie; Jane A Little; Mariana Hildesheim; J Simon R Gibbs; Claudia R Morris; Roberto F Machado; Gregory J Kato; Victor R Gordeuk; Mark T Gladwin
Journal:  Am J Hematol       Date:  2019-09-17       Impact factor: 10.047

4.  Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Authors:  Marilyn J Telen
Journal:  Blood Adv       Date:  2020-07-28

5.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

Review 6.  Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Authors:  Courtney D Fitzhugh; Emmanuel J Volanakis; Ombeni Idassi; Josh A Duberman; Michael R DeBaun; Debra L Friedman
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

Review 7.  Sickle cell disease as an accelerated aging syndrome.

Authors:  Ibrahim M Idris; Edward A Botchwey; Hyacinth I Hyacinth
Journal:  Exp Biol Med (Maywood)       Date:  2022-02-16

8.  Individual Watershed Areas in Sickle Cell Anemia: An Arterial Spin Labeling Study.

Authors:  Hanne Stotesbury; Patrick W Hales; Anna M Hood; Melanie Koelbel; Jamie M Kawadler; Dawn E Saunders; Sati Sahota; David C Rees; Olu Wilkey; Mark Layton; Maria Pelidis; Baba P D Inusa; Jo Howard; Subarna Chakravorty; Chris A Clark; Fenella J Kirkham
Journal:  Front Physiol       Date:  2022-05-03       Impact factor: 4.755

9.  Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.

Authors:  Mohsen Alzahrani; Moussab Damlaj; Neal Jeffries; Bader Alahmari; Avani Singh; Damiano Rondelli; John F Tisdale; Santosh L Saraf; Matthew M Hsieh
Journal:  Br J Haematol       Date:  2021-02-03       Impact factor: 8.615

10.  Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis.

Authors:  Kenneth I Ataga; Victor R Gordeuk; Irene Agodoa; Jennifer A Colby; Kimberly Gittings; Isabel E Allen
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.